MedTrace Logo

Effects of Aripiprazole and Haloperidol on Mesolimbic System Functioning

NCT01161277 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2014-09-12

No results posted yet for this study

Summary

The main objective is to investigate if the brain activation signature of a typical antipsychotic agent is dissociable from a newer drug with a pharmacological profile that differs from both typical and atypical antipsychotics since it is a potent partial D2 agonist. The method used to study this will be functional magnetic resonance imaging (fMRI).

Conditions

Interventions

DRUG

Aripiprazole

Dose: 5-10 mg depending on subject weight

DRUG

Haloperidol

Dose: 1-2 mg depending on subject weight

DRUG

Placebo sugar pill

Dose: 1-2 pills depending on subject weight

Sponsors & Collaborators

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Ole A Andreassen, MD, PhD · Oslo University Hospital, Ullevål

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01161277 on ClinicalTrials.gov